S-EPMC7743015 - Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. - OmicsDI

Unknown

Dataset Information

Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.

ABSTRACT:

SUBMITTER: Hou Y

PROVIDER: S-EPMC7743015 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature